Therapeutic angiogenesis: Recent and future prospects of gene therapy in peripheral artery disease

Current Gene Therapy

Volumn 14, Issue 4, 2014, Pages 300-308

  Tanaka, Michiko ^a   Taketomi, Kikuko ^b   Yonemitsu, Yoshikazu ^a  

^a KYUSHU UNIVERSITY   (Japan)

^b HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Angiogenesis; Clinical trials; Gene therapy; Growth factor; Peripheral artery disease; Plasmid

Indexed keywords

CILOSTAZOL; DEL 1; FIBROBLAST GROWTH FACTOR; HYPOXIA INDUCIBLE FACTOR 1ALPHA; MEMBRANE PROTEIN; NAFTIDROFURYL; SCATTER FACTOR; UNCLASSIFIED DRUG; VASCULOTROPIN; ZINC FINGER PROTEIN; CARRIER PROTEIN; EDIL3 PROTEIN, HUMAN; VASCULOTROPIN A;

ANGIOGENESIS; APOPTOSIS; ARTICLE; CRITICAL LIMB ISCHEMIA; DRUG EFFICACY; DRUG SAFETY; GENE EXPRESSION; GENE TARGETING; GENE THERAPY; HUMAN; INTERMITTENT CLAUDICATION; NONHUMAN; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); SENDAI VIRUS; CLINICAL TRIAL (TOPIC); GENE VECTOR; GENETICS; PERIPHERAL ARTERIAL DISEASE; PROCEDURES;

CARRIER PROTEINS; CLINICAL TRIALS AS TOPIC; FIBROBLAST GROWTH FACTORS; GENETIC THERAPY; GENETIC VECTORS; HEPATOCYTE GROWTH FACTOR; HUMANS; NEOVASCULARIZATION, PHYSIOLOGIC; PERIPHERAL ARTERIAL DISEASE; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84907152765     PISSN: 15665232     EISSN: 18755631     Source Type: Journal    
DOI: 10.2174/156652321404140902124838     Document Type: Article

References (116)

1. Mughal NA, Russell DA, Ponnambalam S, et al. Gene therapy in the treatment of peripheral arterial disease. Br J Surg 2012; 99(1): 6-15.
2. Norgren L, Hiatt WR, Dormandy JA, et al. Inter-society consensus for the management of peripheral arterial disease (TASC II). Eur J Vasc Endovasc Surg 2007; 33(Suppl 1): S1-75.
3. Tiong A, Freedman SB. Gene therapy for cardiovascular disease: the potential of VEGF. Curr Opin Mol Ther 2004; 6(2): 151-9.
4. Go AS, Mozaffarian D, Roger VL, et al. Executive summary: heart disease and stroke statistics: 2013 update. A report from the American Heart Association. Circulation 2013; 127(1): 143-52.
5. Madonna R, Rokosh G. Insights into gene therapy for critical limb ischemia: the devil is in the details. Vascul Pharmacol 2012; 57(1): 10-4.
6. Lumsden AB, Rice TW, Chen C, et al. Peripheral arterial occlusive disease: magnetic resonance imaging and the role of aggressive medical management. World J Surg 2007; 31(4): 695-704.
7. Aboyans V, Criqui MH, Abraham P, et al. Measurement and interpretation of the ankle-brachial index: a scientific statement from the American Heart Association. Circulation 2012; 126(24): 2890-909.
8. Abdulhannan P, Russell DA, Homer-Vanniasinkam S. Peripheral arterial disease: a literature review. Br Med Bull 2012; 104(1): 21-39.
9. Takeshita S, Zheng LP, Brogi E, et al. Therapeutic angiogenesis: a single intraarterial bolus of vascular endothelial growth factor augments revascularization in a rabbit ischemic hind limb model. J Clin Invest 1994; 93(2): 662-70.
10. Sedighiani F, Nikol S. Gene therapy in vascular disease. Surgeon 2011; 9(6): 326-35.
11. Davies MG. Critical limb ischemia: cell and molecular therapies for limb salvage. Methodist Debakey Cardiovasc J 2012; 8(4): 20-7.
12. Berger JS, Hiatt WR. Medical therapy in peripheral artery disease. Circulation 2012; 126(4): 491-500.
13. Germani A, Di Campli C, Pompilio G, et al. Regenerative therapy in peripheral artery disease. Cardiovasc Ther 2009; 27(4): 289-304.
14. Baumgartner I, Pieczek A, Manor O, et al. Constitutive expression of phVEGF165 after intramuscular gene transfer promotes collateral vessel development in patients with critical limb ischemia. Circulation 1998; 97(12): 1114-23.
15. Grochot-Przeczek A, Dulak J, Jozkowicz A. Therapeutic angiogenesis for revascularization in peripheral artery disease. Gene 2013; 525(2): 220-8.
16. Isner JM, Pieczek A, Schainfeld R, et al. Clinical evidence of angiogenesis after arterial gene transfer of phVEGF165 in patient with ischaemic limb. Lancet 1996; 348(9024): 370-4.
17. Bartel RL, Booth E, Cramer C, et al. From bench to bedside: review of gene and cell-based therapies and the slow advancement into phase 3 clinical trials, with a focus on Aastrom's Ixmyelocel-T. Stem Cell Rev 2013; 9(3): 373-83.
18. Ouma GO, Jonas RA, Usman MH, et al. Targets and delivery methods for therapeutic angiogenesis in peripheral artery disease. Vasc Med 2012; 17(3): 174-92.
19. Giacca M, Zacchigna S. VEGF gene therapy: therapeutic angiogenesis in the clinic and beyond. Gene Ther 2012; 19(6): 622-9.
20. Dvorak HF, Brown LF, Detmar M, et al. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am J Pathol 1995; 146(5): 1029-39.
21. Onimaru M, Yonemitsu Y, Fujii T, et al. VEGF-C regulates lymphangiogenesis and capillary stability by regulation of PDGFB. Am J Physiol Heart Circ Physiol 2009; 297(5): H1685-96.
22. Rasmussen HS, Rasmussen CS, Macko J. VEGF gene therapy for coronary artery disease and peripheral vascular disease. Cardiovasc Radiat Med 2002; 3(2): 114-7.
23. Greve JM, Chico TJ, Goldman H, et al. Magnetic resonance angiography reveals therapeutic enlargement of collateral vessels induced by VEGF in a murine model of peripheral arterial disease. J Magn Reson Imaging 2006; 24(5): 1124-32.
24. Pinkenburg O, Pfosser A, Hinkel R, et al. Recombinant adenoassociated virus-based gene transfer of cathelicidin induces therapeutic neovascularization preferentially via potent collateral growth. Hum Gene Ther 2009; 20(2): 159-67.
25. Olea FD, Vera Janavel G, Cuniberti L, et al. Repeated, but not single, VEGF gene transfer affords protection against ischemic muscle lesions in rabbits with hindlimb ischemia. Gene Ther 2009; 16(6): 716-23.
26. Rebar EJ, Huang Y, Hickey R, et al. Induction of angiogenesis in a mouse model using engineered transcription factors. Nat Med 2002; 8(12): 1427-32.
27. Urnov FD, Rebar EJ. Designed transcription factors as tools for therapeutics and functional genomics. Biochem Pharmacol 2002; 64: 919-23.
28. Liu PQ, Rebar EJ, Zhang L, et al. Regulation of an endogenous locus using a panel of designed zinc finger proteins targeted to accessible chromatin regions. Activation of vascular endothelial growth factor A. J Biol Chem 2001; 276: 11323-34.
29. Snowden AW, Zhang L, Urnov F, et al. Repression of vascular endothelial growth factor A in glioblastoma cells using engineered zinc finger transcription factors. Cancer Res 2003; 63: 8968-76.
30. Dent CL, Lau G, Drake EA, et al. Regulation of endogenous gene expression using small molecule-controlled engineered zinc-finger protein transcription factors. Gene Ther 2007; 14: 1362-69.
31. Dai Q, Huang J, Klitzman B, et al. Engineered zinc fingeractivating vascular endothelial growth factor transcription factor plasmid DNA induces therapeutic angiogenesis in rabbits with hindlimb ischemia. Circulation 2004; 110: 2467-75.
32. Xie D, Li Y, Reed EA, et al. An engineeered vascular endothelial growth factor-activating transcription factor induces therapeutic angiogenesis in ApoE knockout mice with hindlimb ischemia. J Vasc Surg 2006; 44: 165-75.
33. Li Y, Hazarika S, Xie D, et al. In mice with type 2 diabetes, a vascular endothelial growth factor (VEGF)-activating transcription factor modulates VEGF signaling and induces therapeutic angiogenesis after hindlimb ischemia. Diabetes 2007; 56: 656-65.
34. Gounis MJ, Spiga MG, Graham RM, et al. Angiogenesis is confined to the transient period of VEGF expression that follows adenoviral gene delivery to ischemic muscle. Gene Ther 2005; 12(9): 762-71.
35. Gowdak LH, Poliakova L, Wang X, et al. Adenovirus-mediated VEGF(121) gene transfer stimulates angiogenesis in normoperfused skeletal muscle and preserves tissue perfusion after induction of ischemia. Circulation 2000; 102(5): 565-71.
36. Simovic D, Isner JM, Ropper AH, et al. Improvement in chronic ischemic neuropathy after intramuscular phVEGF165 gene transfer in patients with critical limb ischemia. Arch Neurol 2001; 58(5): 761-8.
37. Kim HJ, Jang SY, Park JI, et al. Vascular endothelial growth factor-induced angiogenic gene therapy in patients with peripheral artery disease. Exp Mol Med 2004; 36(4): 336-44.
38. Shyu KG, Chang H, Wang BW, et al. Intramuscular vascular endothelial growth factor gene therapy in patients with chronic critical leg ischemia. Am J Med 2003; 114(2): 85-92.
39. Kusumanto YH, van Weel V, Mulder NH, et al. Treatment with intramuscular vascular endothelial growth factor gene compared with placebo for patients with diabetes mellitus and critical limb ischemia: a double-blind randomized trial. Hum Gene Ther 2006; 17(6): 683-91.
40. Makinen K, Manninen H, Hedman M, et al. Increased vascularity detected by digital subtraction angiography after VEGF gene transfer to human lower limb artery: a randomized, placebocontrolled, double-blinded phase II study. Mol Ther 2002; 6(1): 127-33.
41. Rajagopalan S, Shah M, Luciano A, et al. Adenovirus-mediated gene transfer of VEGF(121) improves lower-extremity endothelial function and flow reserve. Circulation 2001; 104(7): 753-5.
42. Rajagopalan S, Trachtenberg J, Mohler E, et al. Phase I study of direct administration of a replication deficient adenovirus vector containing the vascular endothelial growth factor cDNA (CI-1023) to patients with claudication. Am J Cardiol 2002; 90(5): 512-6.
43. Rajagopalan S, Mohler III ER, Lederman RJ, et al. Regional angiogenesis with vascular endothelial growth factor in peripheral arterial disease: a phase II randomized, double-blind, controlled study of adenoviral delivery of vascular endothelial growth factor 121 in patients with disabling intermittent claudication. Circulation 2003; 108(16): 1933-8.
44. Presta M, Dell’Era P, Mitola S, et al. Fibroblast growth factor/fibroblast growth factor receptor system in angiogenesis. Cytokine Growth Factor Rev 2005; 16(2): 159-78.
45. Witzenbichler B, Mahfoudi A, Soubrier F, et al. Intramuscular gene transfer of fibroblast growth factor-1 using improved pCOR plasmid design stimulates collateral formation in a rabbit ischemic hindlimb model. J Mol Med 2006; 84(6): 491-502.
46. Tabata H. Arterial gene transfer of acidic fibroblast growth factor for therapeutic angiogenesis in vivo: critical role of secretion signal in use of naked DNA. Cardiovasc Res 1997; 35(3): 470-9.
47. Caron A, Michelet S, Caron A, et al. Human FGF-1 gene transfer promotes the formation of collateral vessels and arterioles in ischemic muscles of hypercholesterolemic hamsters. J Gene Med 2004; 6(9): 1033-45.
48. Comerota AJ, Throm RC, Miller KA, et al. Naked plasmid DNA encoding fibroblast growth factor type 1 for the treatment of endstage unreconstructible lower extremity ischemia: preliminary results of a phase I trial. J Vasc Surg 2002; 35(5): 930-6.
49. Baumgartner I, Chronos N, Comerota A, et al. Local gene transfer and expression following intramuscular administration of FGF-1 plasmid DNA in patients with critical limb ischemia. Mol Ther 2009; 17(5): 914-21.
50. Nikol S, Baumgartner I, Belle EV, et al. Therapeutic angiogenesis with intramuscular NV1FGF improves amputation-free survival in patients with critical limb ischemia. Mol Ther 2008; 16(5): 972-8.
51. Niebuhr A, Henry T, Goldman J, et al. Long-term safety of intramuscular gene transfer of non-viral FGF1 for peripheral artery disease. Gene Ther 2012; 19(3): 264-70.
52. Adis R&D Profile. Riferminogene pecaplasmide. Am J Cardiovasc Drugs 2010; 10(5): 343-6.
53. Belch J, Hiatt WR, Baumgartner I, et al. Effect of fibroblast growth factor NV1FGF on amputation and death: a randomised placebocontrolled trial of gene therapy in critical limb ischaemia. Lancet 2011; 377(9781): 1929-37.
54. Lazarous DF, Unger EF, Epstein SE, et al. Basic fibroblast growth factor in patients with intermittent claudication: results of a phase I trial. J Am Coll Cardiol 2000; 36(4): 1239-44.
55. Lederman RJ, Mendelsohn FO, Anderson RD, et al. Therapeutic angiogenesis with recombinant fibroblast growth factor-2 for intermittent claudication (the TRAFFIC study): a randomised trial. Lancet 2002; 359(9323): 2053-8.
56. Aviles RJ, Annex BH, Lederman RJ. Testing clinical therapeutic angiogenesis using basic fibroblast growth factor (FGF-2). Br J Pharmacol 2003; 140(4): 637-46.
57. Fujii T, Yonemitsu Y, Onimaru M, et al. Nonendothelial mesenchymal cell-derived MCP-1 is required for FGF-2-mediated therapeutic neovascularization: critical role of the inflammatory/arteriogenic pathway. Arterioscler Thromb Vasc Biol 2006; 26(11): 2483-9.
58. Tsutsumi N, Yonemitsu Y, Shikada Y, et al. Essential role of PDGFRalpha-p70S6K signaling in mesenchymal cells during therapeutic and tumor angiogenesis in vivo: role of PDGFRalpha during angiogenesis. Circ Res 2004; 94(9): 1186-94.
59. Layman H, Rahnemai-Azar AA, Pham SM, et al. Synergistic angiogenic effect of codelivering fibroblast growth factor 2 and granulocyte-colony stimulating factor from fibrin scaffolds and bone marrow transplantation in critical limb ischemia. Tissue Eng Part A 2011; 17(1-2): 243-54.
60. Safi Jr J, DiPaula Jr AF, Riccioni T, et al. Adenovirus-mediated acidic fibroblast growth factor gene transfer induces angiogenesis in the nonischemic rabbit heart. Microvasc Res 1999; 58(3): 238-49.
61. Layman H, Sacasa M, Murphy AE, et al. Co-delivery of FGF-2 and G-CSF from gelatin-based hydrogels as angiogenic therapy in a murine critical limb ischemic model. Acta Biomater 2009; 5(1): 230-9.
62. Layman H, Spiga MG, Brooks T, et al. The effect of the controlled release of basic fibroblast growth factor from ionic gelatin-based hydrogels on angiogenesis in a murine critical limb ischemic model. Biomaterials 2007; 28(16): 2646-54.
63. Yonemitsu Y, Kitson C, Ferrari S, et al. Efficient gene transfer to airway epithelium using recombinant Sendai virus. Nat Biotechnol 2000; 18(9): 970-3.
64. Shoji T, Yonemitsu Y, Komori K, et al. Intramuscular gene transfer of FGF-2 attenuates endothelial dysfunction and inhibits intimal hyperplasia of vein grafts in poor-runoff limbs of rabbit. Am J Physiol Heart Circ Physiol 2003; 285(1): H173-82.
65. Onimaru M, Yonemitsu Y, Tanii M, et al. Fibroblast growth factor-2 gene transfer can stimulate hepatocyte growth factor expression irrespective of hypoxia-mediated downregulation in ischemic limbs. Circ Res 2002; 91(10): 923-30.
66. Masaki I, Yonemitsu Y, Yamashita A, et al. Angiogenic gene therapy for experimental critical limb ischemia: acceleration of limb loss by overexpression of vascular endothelial growth factor 165 but not of fibroblast growth factor-2. Circ Res 2002; 90(9): 966-73.
67. Yonemitsu Y, Matsumoto T, Itoh H, et al. DVC1-0101 to treat peripheral arterial disease: a phase I/IIa open-label dose-escalation clinical trial. Mol Ther 2013; 21(3): 707-14.
68. Tanaka M, Matsumoto T. Morisaki K, et al. Efficacy and safety of DVC1-0101 for intermittent claudication secondary to peripheral artery disease: study protocol of a randomized phase IIb trial. J Clin Trials 2012; 3: 138.
69. Matsumoto K, Nakamura T. Emerging multipotent aspects of hepatocyte growth factor. J Biochem 1996; 119(4): 591-600.
70. Bussolino F, Di Renzo MF, Ziche M, et al. Hepatocyte growth factor is a potent angiogenic factor which stimulates endothelial cell motility and growth. J Cell Biol 1992; 119(3): 629-41.
71. Yang ZJ, Xu SL, Chen B, et al. Hepatocyte growth factor plays a critical role in the regulation of cytokine production and induction of endothelial progenitor cell mobilization: a pilot gene therapy study in patients with coronary heart disease. Clin Exp Pharmacol Physiol 2009; 36(8): 790-6.
72. Morishita R, Aoki M, Yo Y, Ogihara T. Hepatocyte growth factor as cardiovascular hormone: role of HGF in the pathogenesis of cardiovascular disease. Endocrine J 2002; 49(3): 273-84.
73. Su GH, Sun YF, Lu YX, et al. Hepatocyte growth factor genemodified bone marrow-derived mesenchymal stem cells transplantation promotes angiogenesis in a rat model of hindlimb ischemia. J Huazhong Univ Sci Technol Med Sci 2013; 33(4): 511-9.
74. Cowin AJ, Kallincos N, Hatzirodos N, et al. Hepatocyte growth factor and macrophage-stimulating protein are upregulated during excisional wound repair in rats. Cell Tissue Res 2001; 306(2): 239-50.
75. Taniyama Y, Morishita R, Aoki M, et al. Therapeutic angiogenesis induced by human hepatocyte growth factor gene in rat and rabbit hindlimb ischemia models: preclinical study for treatment of peripheral arterial disease. Gene Ther 2001; 8(3): 181-9.
76. Morishita R, Nakamura S, Hayashi S, et al. Therapeutic angiogenesis induced by human recombinant hepatocyte growth factor in rabbit hind limb ischemia model as cytokine supplement therapy. Hypertension 1999; 33(6): 1379-84.
77. Powell RJ, Simons M, Mendelsohn FO, et al. Results of a doubleblind, placebo-controlled study to assess the safety of intramuscular injection of hepatocyte growth factor plasmid to improve limb perfusion in patients with critical limb ischemia. Circulation 2008; 118(1): 58-65.
78. Powell RJ, Goodney P, Mendelsohn FO, et al. Safety and efficacy of patient specific intramuscular injection of HGF plasmid gene therapy on limb perfusion and wound healing in patients with ischemic lower extremity ulceration: results of the HGF-0205 trial. J Vasc Surg 2010; 52(6): 1525-30.
79. Powell RJ. Update on clinical trials evaluating the effect of biologic therapy in patients with critical limb ischemia. J Vasc Surg 2012; 56(1): 264-6.
80. Morishita R, Aoki M, Hashiya N, et al. Safety evaluation of clinical gene therapy using hepatocyte growth factor to treat peripheral arterial disease. Hypertension 2004; 44(2): 203-9.
81. Morishita R, Makino H, Aoki M, et al. Phase I/IIa clinical trial of therapeutic angiogenesis using hepatocyte growth factor gene transfer to treat critical limb ischemia. Arterioscler Thromb Vasc Biol 2011; 31(3): 713-20.
82. Makino H, Aoki M, Hashiya N, et al. Long-term follow-up evaluation of results from clinical trial using hepatocyte growth factor gene to treat severe peripheral arterial disease. Arterioscler Thromb Vasc Biol 2012; 32(10): 2503-9.
83. Shigematsu H, Yasuda K, Iwai T, et al. Randomized, double-blind, placebo-controlled clinical trial of hepatocyte growth factor plasmid for critical limb ischemia. Gene Ther 2010; 17(9): 1152-61.
84. Henry TD, Hirsch AT, Goldman J, et al. Safety of a non-viral plasmid-encoding dual isoforms of hepatocyte growth factor in critical limb ischemia patients: a phase I study. Gene Ther 2011; 18(8): 788-94.
85. Gu Y, Zhang J, Guo L, et al. A phase I clinical study of naked DNA expressing two isoforms of hepatocyte growth factor to treat patients with critical limb ischemia. J Gene Med 2011; 13(11): 602-10.
86. Hahn W, Pyun WB, Kim DS, et al. Enhanced cardioprotective effects by coexpression of two isoforms of hepatocyte growth factor from naked plasmid DNA in a rat ischemic heart disease model. J Gene Med 2011; 13(10): 549-55.
87. Pyun WB, Hahn W, Kim DS, et al. Naked DNA expressing two isoforms of hepatocyte growth factor induces collateral artery augmentation in a rabbit model of limb ischemia. Gene Ther 2010; 17(12): 1442-52.
88. ClinicalTrials. gov. A service of the U. S. National Institutes of Health [Online]. Available at: http://clinicaltrials. gov/; NCT01064440.
89. Rey S, Semenza GL. Hypoxia-inducible factor-1-dependent mechanisms of vascularization and vascular remodelling. Cardiovasc Res 2010; 86(2): 236-42.
90. Safran M, Kaelin WG Jr. HIF hydroxylation and the mammalian oxygen-sensing pathway. J Clin Invest 2003; 111(6): 779-83.
91. Semenza GL. Regulation of physiological responses to continuous and intermittent hypoxia by hypoxia-inducible factor 1. Exptl Physiol 2006; 91(5): 803-6.
92. Huang LE, Arany Z, Livingston DM, et al. Activation of hypoxiainducible transcription factor depends primarily upon redoxsensitive stabilization of its alpha subunit. J Biol Chem 1996; 271(50): 32253-9.
93. Webb JD, Coleman ML, Pugh CW. Hypoxia, hypoxia-inducible factors (HIF), HIF hydroxylases and oxygen sensing. Cell Mol Life Sci 2009; 66(22): 3539-54.
94. Pugh CW, Ratcliffe PJ. Regulation of angiogenesis by hypoxia: role of the HIF system. Nat Med 2003; 9(6): 677-84.
95. Kaelin WG Jr, Ratcliffe PJ. Oxygen sensing by metazoans: the central role of the HIF hydroxylase pathway. Mol Cell 2008; 30(4): 393-402.
96. Sarkar K, Fox-Talbot K, Steenbergen C, et al. Adenoviral transfer of HIF-1alpha enhances vascular responses to critical limb ischemia in diabetic mice. Proc Natl Acad Sci U S A 2009; 106(44): 18769-74.
97. Patel TH, Kimura H, Weiss CR, et al. Constitutively active HIF-1alpha improves perfusion and arterial remodeling in an endovascular model of limb ischemia. Cardiovasc Res 2005; 68(1): 144-54.
98. Rey S, Lee K, Wang CJ, et al. Synergistic effect of HIF-1alpha gene therapy and HIF-1-activated bone marrow-derived angiogenic cells in a mouse model of limb ischemia. Proc Natl Acad Sci U S A 2009; 106(48): 20399-404.
99. Bosch-Marce M, Okuyama H, Wesley JB, et al. Effects of aging and hypoxia-inducible factor-1 activity on angiogenic cell mobilization and recovery of perfusion after limb ischemia. Circ Res 2007; 101(12): 1310-8.
100. Vincent KA. Angiogenesis is induced in a rabbit model of hindlimb ischemia by naked DNA encoding an HIF-1alpha/VP16 hybrid transcription factor. Circulation 2000; 102(18): 2255-61.
101. Rajagopalan S, Olin J, Deitcher S, et al. Use of a constitutively active hypoxia-inducible factor-1alpha transgene as a therapeutic strategy in no-option critical limb ischemia patients: phase I doseescalation experience. Circulation 2007; 115(10): 1234-43.
102. Creager MA, Olin JW, Belch JJ, et al. Effect of hypoxia-inducible factor-1alpha gene therapy on walking performance in patients with intermittent claudication. Circulation 2011; 124(16): 1765-73.
103. Zhong J, Eliceiri B, Stupack D, et al. Neovascularization of ischemic tissues by gene delivery of the extracellular matrix protein Del-1. J Clin Invest 2003; 112(1): 30-41.
104. Ho HK, Jang JJ, Kaji S, et al. Developmental endothelial locus-1 (Del-1), a novel angiogenic protein: its role in ischemia. Circulation 2004; 109(10): 1314-9.
105. Quezada A, Larson J, French M, et al. Biodistribution and safety studies of hDel-1 plasmid-based gene therapy in mouse and rabbit models. J Pharm Pharmacol 2004; 56(2): 177-85.
106. Grossman PM, Mendelsohn F, Henry TD, et al. Results from a phase II multicenter, double-blind placebo-controlled study of Del 1 (VLTS-589) for intermittent claudication in subjects with peripheral arterial disease. Am Heart J 2007; 153(5): 874-80.
107. Davies MG. Critical limb ischemia: cell and molecular therapies for limb salvage. Methodist DeBakey Cardiovasc J 2012; 8(4): 20-7.
108. De Haro J, Acin F, Lopez-Quintana A, et al. Meta-analysis of randomized, controlled clinical trials in angiogenesis: gene and cell therapy in peripheral arterial disease. Heart Vessels 2009; 24(5): 321-8.
109. Gupta R, Tongers J, Losordo DW. Human studies of angiogenic gene therapy. Circ Res 2009; 105(8): 724-36.
110. Brass EP, Jiao J, Hiatt W. Optimal assessment of baseline treadmill walking performance in claudication clinical trials. Vasc Med 2007; 12(2): 97-103.
111. Yla-Herttuala S, Alitalo K. Gene transfer as a tool to induce therapeutic vascular growth. Nat Med 2003; 9(6): 694-701.
112. Jazwa A, Jozkowicz A, Dulak J. New vectors and strategies for cardiovascular gene therapy. Curr Gene Ther 2007; 7(1): 7-23.
113. Yeh JL, Giordano FJ. Gene-based therapeutic angiogenesis. Semin Thorac Cardiovasc Surg 2003; 15(3): 236-49.
114. Escoffre JM, Zeghimi A, Novell A, et al. In-vivo gene delivery by sonoporation: recent progress and prospects. Curr Gene Ther 2013; 13(1): 2-14.
115. Freedman SB. Clinical trials of gene therapy for atherosclerotic cardiovascular disease. Curr Opin Lipidol 2002; 13(6): 653-61.
116. Tongers J, Roncalli JG, Losordo DW. Therapeutic angiogenesis for critical limb ischemia: microvascular therapies coming of age. Circulation 2008; 118(1): 9-16.